Aortic valve disorder

Summary

Aortic valve disorder (MONDO:0003803) is a disease (an umbrella term covering 5 Mondo subtypes) with 2 cohort genes (19 GWAS associations across 15 studies) and 184 clinical trials. Top therapeutic interventions include sodium chloride, aminolevulinic acid, and apixaban.

At a glance

• Umbrella term: 5 Mondo subtypes
• Cohort genes: 2
• GWAS associations: 19
• ClinVar variants: 7
• Clinical trials: 184

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	aortic valve disorder
Mondo ID	MONDO:0003803
EFO	EFO:0009531
DOID	DOID:62
ICD-11	1609206873
NCIT	C78650
UMLS	C1260873
MedGen	226776
Anatomy (UBERON)	UBERON:0002137
Is cancer (heuristic)	no

Also known as: aortic valve disease · aortic valve disease or disorder · aortic valve disorder · disease of aortic valve · disease or disorder of aortic valve · disorder of aortic valve

Data availability: 7 ClinVar variants · 19 GWAS associations (15 studies) · 1 GenCC gene-disease record.

Disease family

An umbrella term covering 5 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › heart valve disorder › aortic valve disorder

Related subtypes (3): tricuspid valve disorder, pulmonary valve disorder, mitral valve disorder

Subtypes (5): aortic valve calcification, aortic valve insufficiency, aortic valve prolapse, familial bicuspid aortic valve, aortic valve stenosis

Genetics & variants

GWAS landscape

19 GWAS associations across 15 studies. Top hits map to 9 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs74617384	3e-69	LPA	A	0.34
rs6702619	1e-41	LINC01708	T	0.14
chr2:145796251	7e-25		G	0.1
chr7:22770149	3e-21		G	0.1
chr11:61557803	3e-21		T	0.1
rs10192407	4e-21	TEX41	A	0.1
rs1554606	9e-20	IL6	T	0.09
rs174551	3e-19	FADS2, FADS1	T	0.1
rs117202424	1e-15	CEP85L	G	0.18
rs55872725	8e-15	FTO	C	0.08
chr3:169207475	2e-14		C	0.08
rs2421651	2e-14	MECOM	A	0.08
chr15:43040387	1e-13		G	0.09
chr22:38105810	7e-13		C	0.08
rs11153733	7e-13	SLC35F1 - CEP85L	T	0.17
rs56094641	6e-12	FTO	A	0.07
rs148050993	5e-07	LARP1BP1 - TECRL	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475914	Verma A	2024	20,077	418,636	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473558	UK Biobank Whole-Genome Sequencing Consortium	2025	9,013	449,427	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90079996	Backman JD	2021	3,782	383,293	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083982	Backman JD	2021	3,782	383,293	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90477842	Verma A	2024	2,397	117,197	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480120	Verma A	2024	2,397	117,197	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90103406	Fitzgerald T	2022	2,181	168,576	CNest: A novel copy number association discovery method uncovers 862 new associations from 200,629 whole-exome sequence datasets in the UK Biobank.
GCST90477841	Verma A	2024	1,358	57,575	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436056	Zhou W	2018	1,260	402,421	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90652165	Liu TY	2025	717	232,474	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	17

MAF distribution

Bucket	Variants
common (>=0.05)	15
low_freq (0.01-0.05)	1
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intron_variant	9
unknown	6
intergenic_variant	2

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs74617384	6	160576086	A>C,G,T	0.067	intron_variant	LPA	3e-69	Tier 4: intronic/intergenic
rs6702619	1	99580690	T>G	0.488	intron_variant	LINC01708	1e-41	Tier 4: intronic/intergenic
chr2:145796251				0.453			7e-25	Tier 4: intronic/intergenic
chr7:22770149				0.447			3e-21	Tier 4: intronic/intergenic
chr11:61557803				0.34			3e-21	Tier 4: intronic/intergenic
rs10192407	2	145056811	A>T	0.463	intron_variant	TEX41	4e-21	Tier 4: intronic/intergenic
rs1554606	7	22729088	T>A,G	0.41	intron_variant	IL6	9e-20	Tier 4: intronic/intergenic
rs174551	11	61806212	T>A,C	0.299	intron_variant	FADS2, FADS1	3e-19	Tier 4: intronic/intergenic
rs117202424	6	118500543	G>A	0.051	intron_variant	CEP85L	1e-15	Tier 4: intronic/intergenic
rs55872725	16	53775211	C>G,T	0.404	intron_variant	FTO	8e-15	Tier 4: intronic/intergenic
chr3:169207475				0.487			2e-14	Tier 4: intronic/intergenic
rs2421651	3	169488705	A>C,G	0.465	intron_variant	MECOM	2e-14	Tier 4: intronic/intergenic
chr15:43040387				0.209			1e-13	Tier 4: intronic/intergenic
chr22:38105810				0.408			7e-13	Tier 4: intronic/intergenic
rs11153733	6	118403564	T>C	0.04	intergenic_variant	SLC35F1 - CEP85L	7e-13	Tier 4: intronic/intergenic
rs56094641	16	53772541	A>G,T	0.332	intron_variant	FTO	6e-12	Tier 4: intronic/intergenic
rs148050993	4	63616957	T>A		intergenic_variant	LARP1BP1 - TECRL	5e-07	Tier 4: intronic/intergenic

ClinVar germline variants

7 retrieved; paginated sample, class counts are floors:

6 conflicting classifications of pathogenicity, 1 likely benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
264541	NM_017617.5(NOTCH1):c.1981G>A (p.Gly661Ser)	NOTCH1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
449324	NM_017617.5(NOTCH1):c.6481C>T (p.Pro2161Ser)	NOTCH1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
451668	NM_017617.5(NOTCH1):c.2558_2560del (p.Phe853del)	NOTCH1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
544188	NM_017617.5(NOTCH1):c.4271T>C (p.Leu1424Ser)	NOTCH1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
836011	NM_017617.5(NOTCH1):c.691G>A (p.Gly231Ser)	NOTCH1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
864459	NM_017617.5(NOTCH1):c.2735G>A (p.Arg912Gln)	NOTCH1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
839770	NM_017617.5(NOTCH1):c.6393C>T (p.Gly2131=)	NOTCH1	Likely benign	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 1 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
PDIA2	Limited	Autosomal dominant	aortic valve disorder

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
NOTCH1	Orphanet:402075	Familial bicuspid aortic valve
NOTCH1	Orphanet:974	Adams-Oliver syndrome

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
PDIA2	HGNC:14180	ENSG00000185615	Q13087	Protein disulfide-isomerase A2	gencc
NOTCH1	HGNC:7881	ENSG00000148400	P46531	Neurogenic locus notch homolog protein 1	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
PDIA2	Protein disulfide-isomerase A2	Acts as an intracellular estrogen-binding protein.
NOTCH1	Neurogenic locus notch homolog protein 1	Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination.

Protein-family classification

Druggable: 1 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Scaffold/PPI	1	8.6×	0.160
Enzyme (other)	1	6.0×	0.160

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
PDIA2	Enzyme (other)	yes	5.3.4.1	Prot_disulphide_isomerase, Thioredoxin_domain, Thioredoxin_CS
NOTCH1	Scaffold/PPI	no		EGF-type_Asp/Asn_hydroxyl_site, EGF, Notch_dom

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
body of pancreas	1
cerebellar hemisphere	1
right hemisphere of cerebellum	1
colonic epithelium	1
ventricular zone	1
visceral pleura	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
PDIA2	180	tissue_specific	marker	body of pancreas, right hemisphere of cerebellum, cerebellar hemisphere
NOTCH1	272	ubiquitous	marker	ventricular zone, colonic epithelium, visceral pleura

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
NOTCH1	7,411
PDIA2	2,926

Structural data

PDB: 1 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
NOTCH1	P46531	29

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
PDIA2	Q13087	86.97

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 24. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling	1	1142.0×	0.007	NOTCH1
Defective LFNG causes SCDO3	1	1142.0×	0.007	NOTCH1
Pre-NOTCH Processing in the Endoplasmic Reticulum	1	951.7×	0.007	NOTCH1
Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant	1	815.7×	0.007	NOTCH1
Regulation of NFE2L2 gene expression	1	713.8×	0.007	NOTCH1
NFE2L2 regulating tumorigenic genes	1	475.8×	0.007	NOTCH1
RUNX3 regulates NOTCH signaling	1	407.9×	0.007	NOTCH1
Constitutive Signaling by NOTCH1 HD Domain Mutants	1	380.7×	0.007	NOTCH1
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells	1	356.9×	0.007	NOTCH1
Pre-NOTCH Processing in Golgi	1	317.2×	0.007	NOTCH1
MECP2 regulates neuronal receptors and channels	1	300.5×	0.007	NOTCH1
NOTCH4 Intracellular Domain Regulates Transcription	1	285.5×	0.007	NOTCH1
NOTCH3 Intracellular Domain Regulates Transcription	1	219.6×	0.008	NOTCH1
Notch-HLH transcription pathway	1	203.9×	0.008	NOTCH1
Formation of paraxial mesoderm	1	203.9×	0.008	NOTCH1
Activated NOTCH1 Transmits Signal to the Nucleus	1	178.4×	0.008	NOTCH1
Nuclear events stimulated by ALK signaling in cancer	1	163.1×	0.009	NOTCH1
Developmental Lineage of Pancreatic Acinar Cells	1	150.3×	0.009	PDIA2
NOTCH1 Intracellular Domain Regulates Transcription	1	119.0×	0.010	NOTCH1
Somitogenesis	1	116.5×	0.010	NOTCH1
Constitutive Signaling by NOTCH1 PEST Domain Mutants	1	98.5×	0.011	NOTCH1
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	1	98.5×	0.011	NOTCH1
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	1	73.2×	0.014	NOTCH1
Pre-NOTCH Transcription and Translation	1	61.4×	0.016	NOTCH1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
coronary sinus valve morphogenesis	1	8426.0×	0.002	NOTCH1
Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation	1	8426.0×	0.002	NOTCH1
foregut morphogenesis	1	8426.0×	0.002	NOTCH1
regulation of epithelial cell proliferation involved in prostate gland development	1	8426.0×	0.002	NOTCH1
venous endothelial cell differentiation	1	8426.0×	0.002	NOTCH1
endocardium morphogenesis	1	4213.0×	0.002	NOTCH1
coronary vein morphogenesis	1	4213.0×	0.002	NOTCH1
cardiac right atrium morphogenesis	1	4213.0×	0.002	NOTCH1
growth involved in heart morphogenesis	1	4213.0×	0.002	NOTCH1
obsolete negative regulation of cell proliferation involved in heart valve morphogenesis	1	4213.0×	0.002	NOTCH1
cell differentiation in spinal cord	1	4213.0×	0.002	NOTCH1
positive regulation of aorta morphogenesis	1	4213.0×	0.002	NOTCH1
mitral valve formation	1	2808.7×	0.002	NOTCH1
cardiac chamber formation	1	2808.7×	0.002	NOTCH1
auditory receptor cell fate commitment	1	2808.7×	0.002	NOTCH1
retinal cone cell differentiation	1	2808.7×	0.002	NOTCH1
secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development	1	2808.7×	0.002	NOTCH1
cardiac vascular smooth muscle cell development	1	2808.7×	0.002	NOTCH1
vasculogenesis involved in coronary vascular morphogenesis	1	2808.7×	0.002	NOTCH1
regulation of cell adhesion involved in heart morphogenesis	1	2808.7×	0.002	NOTCH1
distal tubule development	1	2808.7×	0.002	NOTCH1
chemical synaptic transmission, postsynaptic	1	2808.7×	0.002	NOTCH1
apoptotic process involved in embryonic digit morphogenesis	1	2808.7×	0.002	NOTCH1
positive regulation of apoptotic process involved in morphogenesis	1	2808.7×	0.002	NOTCH1
negative regulation of pro-B cell differentiation	1	2808.7×	0.002	NOTCH1
negative regulation of endothelial cell chemotaxis	1	2808.7×	0.002	NOTCH1
inhibition of neuroepithelial cell differentiation	1	2106.5×	0.002	NOTCH1
cardiac right ventricle formation	1	2106.5×	0.002	NOTCH1
cell migration involved in endocardial cushion formation	1	2106.5×	0.002	NOTCH1
negative regulation of extracellular matrix constituent secretion	1	2106.5×	0.002	NOTCH1

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

2 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Evogliptin	Phase 2
Rivaroxaban	Phase 2

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
NOTCH1	1	2
PDIA2	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
VAREGACESTAT	2	NOTCH1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
NOTCH1	23	Binding:19, ADMET:4
PDIA2	2	ADMET:2

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PDIA2	5.3.4.1	protein disulfide-isomerase

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
VAREGACESTAT	2	NOTCH1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	1	NOTCH1
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	1	PDIA2
E	Difficult family or no structure, no drug	0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
PDIA2	2	—

Clinical trials & evidence

Clinical trials

Clinical trials: 184.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	166
PHASE4	10
PHASE3	4
PHASE2	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01536717	PHASE4	SUSPENDED	Comparison of the Local Anaesthetics Articaine and Bupivacaine in Treatment of Acute Sternum Pain After Heart Surgery
NCT01559298	PHASE4	COMPLETED	Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial
NCT01619982	PHASE4	COMPLETED	Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
NCT02247128	PHASE4	COMPLETED	Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
NCT02640794	PHASE4	COMPLETED	Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI
NCT03121053	PHASE4	UNKNOWN	Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement
NCT03807921	PHASE4	COMPLETED	Anticoagulation for Aortic Bioprosthesis (ANTIPRO)
NCT04437303	PHASE4	COMPLETED	Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)
NCT05076604	PHASE4	COMPLETED	Effects of Microplegia on Transfusion Rates After Cardiac Surgery
NCT06235424	PHASE4	UNKNOWN	Del Nido Versus HTK Cardioplegia in Adult Aortic Valve Replacement
NCT05162742	PHASE3	ACTIVE_NOT_RECRUITING	Colchicine and Inflammation in Aortic Stenosis
NCT05687448	PHASE3	NOT_YET_RECRUITING	DIrect Oral Anticoagulation and Bioprothesis Aortic Valve
NCT02098772	PHASE3	COMPLETED	Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol
NCT04142658	PHASE3	TERMINATED	PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
NCT02128841	PHASE2	TERMINATED	Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
NCT03163329	PHASE2	UNKNOWN	The Safety and Effectiveness of Transcatheter Aortic Valve Raplacemet in Intermediate Risk Patients With Bicuspid Aortic Stenosis
NCT03305536	PHASE2	UNKNOWN	Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7)
NCT07027670	PHASE2	COMPLETED	Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery
NCT02153307	Not specified	RECRUITING	Ambulatory Electrocardiographic Monitoring for the Detection of High-Degree Atrio-Ventricular Block in Patients With New-onset PeRsistent LEft Bundle Branch Block After Transcatheter Aortic Valve Implantation. The MARE Study
NCT02673931	Not specified	ACTIVE_NOT_RECRUITING	GLP-1 and Hyperoxia for Organ Protection in Heart Surgery
NCT03440697	Not specified	ACTIVE_NOT_RECRUITING	Pathogenetic Basis of Aortopathy and Aortic Valve Disease
NCT03444259	Not specified	ACTIVE_NOT_RECRUITING	Prospective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients
NCT03453567	Not specified	ACTIVE_NOT_RECRUITING	Evaluation of Effectiveness and Safety of Aortic Valve Replacement in Routine Clinical Practice
NCT03851068	Not specified	ACTIVE_NOT_RECRUITING	Early Feasibility Study for the Foldax Tria Aortic Heart Valve
NCT03924661	Not specified	ACTIVE_NOT_RECRUITING	SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy
NCT04149600	Not specified	ACTIVE_NOT_RECRUITING	Identification of Genetic Causes of Calcific Aortic Valve Disease
NCT04415047	Not specified	ACTIVE_NOT_RECRUITING	The JenaValve ALIGN-AR Pivotal Trial
NCT04430972	Not specified	NOT_YET_RECRUITING	Immune Responsiveness and Outcome After Aortic Valve Surgery (Measure)
NCT04754217	Not specified	RECRUITING	Valved Graft PMCF Study
NCT04864145	Not specified	RECRUITING	Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation
NCT05082454	Not specified	ACTIVE_NOT_RECRUITING	Post Market Clinical Follow-Up Study in Patients Treated With the On-X Ascending Aortic Prosthesis (AAP)
NCT05093764	Not specified	RECRUITING	Quantification of Debris Captured Using TCEP During VIV TAVR With BVF
NCT05295628	Not specified	ACTIVE_NOT_RECRUITING	Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
NCT05411055	Not specified	ACTIVE_NOT_RECRUITING	Aortic Valve Neocuspidization With Glutaraldehyde-Treated Autologous Pericardium (Ozaki Procedure)
NCT05439863	Not specified	RECRUITING	TAVR for Aortic Valve Disease
NCT05536310	Not specified	NOT_YET_RECRUITING	TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease
NCT05635227	Not specified	RECRUITING	Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery
NCT05758909	Not specified	ACTIVE_NOT_RECRUITING	Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation
NCT05932615	Not specified	ENROLLING_BY_INVITATION	ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05941455	Not specified	NOT_YET_RECRUITING	A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SODIUM CHLORIDE	4	2
AMINOLEVULINIC ACID	4	1
APIXABAN	4	1
ARTICAINE	4	1
ASPIRIN	4	1
CEFAZOLIN	4	1
COLCHICINE	4	1
DEXAMETHASONE PHOSPHORIC ACID	4	1
HEXACHLOROPHENE	4	1
HYDROXYETHYL STARCH 130/0.4	4	1
SODIUM BICARBONATE	4	1
WARFARIN	4	1
CHEMBL5282669	0	1